Zhu Qing-Li, Faquin William C, Samir Anthony E
1 Department of Ultrasound, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.
2 Department of Radiology, Abdominal Imaging and Intervention, Massachusetts General Hospital, Harvard Medical School, White 270, 55 Fruit St, Boston, MA 02114.
AJR Am J Roentgenol. 2015 Oct;205(4):861-5. doi: 10.2214/AJR.14.13984.
The purpose of this article is to investigate whether specific clinical and sonographic characteristics are predictive of a benign Afirma test result.
We conducted a retrospective study of Afirma gene expression classifier analysis performed in 44 patients with 45 indeterminate thyroid fine-needle aspiration (FNA) cytologic results between March 2013 and April 2014. Of these, 33 of 45 nodules (73.3%) were repeat atypia of undetermined significance (AUS) and follicular lesions of undetermined significance (FLUS), or follicular neoplasm (FN) and suspicious for a follicular neoplasm (SFN) before Afirma testing.
Of the 45 nodules, 21 (46.7%) were cytologically diagnosed as FLUS, 16 (35.6%) were diagnosed as AUS, and eight (17.8%) were diagnosed as FN or SFN. By Afirma testing, 23 of the 45 nodules (51.1%) were benign, 21 (46.7%) were suspicious, and one (2.2%) had nondiagnostic results. The mean (± SD) nodule size was smaller in the Afirma-benign group than in the Afirma-suspicious group (1.8 ± 0.8 cm [95% CI, 1.4-2.1] vs 2.2 ± 0.8 cm [95% CI, 1.8-2.6]; p < 0.035). No sonographic feature was statistically significantly different between the Afirma-benign and -suspicious groups, including nodule solidity (p = 0.225), echogenicity (p = 0.543), calcification (p = 0.542), and hypervascularity (p = 0.976). All nodules were ovoid shaped and had circumscribed margins in both Afirma groups.
Smaller nodule size was the only characteristic associated with a benign diagnosis on Afirma testing. Sonographic characteristics are not helpful in cases that had a repeat indeterminate FNA finding before Afirma testing.
本文旨在研究特定的临床和超声特征是否能预测阿菲玛检测结果为良性。
我们对2013年3月至2014年4月期间44例患者的45份甲状腺细针穿刺(FNA)细胞学检查结果为不确定的病例进行了阿菲玛基因表达分类分析的回顾性研究。其中,45个结节中的33个(73.3%)在阿菲玛检测前为意义不明确的非典型增生(AUS)、意义不明确的滤泡性病变(FLUS)、滤泡性腺瘤(FN)或可疑滤泡性腺瘤(SFN)。
45个结节中,21个(46.7%)细胞学诊断为FLUS,16个(35.6%)诊断为AUS,8个(17.8%)诊断为FN或SFN。通过阿菲玛检测,45个结节中有23个(51.1%)为良性,21个(46.7%)为可疑,1个(2.2%)结果无法诊断。阿菲玛检测为良性组的结节平均(±标准差)大小小于阿菲玛检测为可疑组(1.8±0.8 cm [95% CI,1.4 - 2.1] 对比 2.2±0.8 cm [95% CI,1.8 - 2.6];p < 0.035)。阿菲玛检测为良性组和可疑组之间的超声特征在统计学上无显著差异,包括结节实性(p =